[1] Interim guidance for country validation of viral hepatitis elimination. Geneva: World Health Organization,2021.
[2] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403.
[3] 尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志, 2023, 26(03): 457-78.
[4] Xia Y, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential[J]. Antiviral Res, 2020, 180: 104824.
[5] Bourne EJ, Dienstag JL, Lopez VA, et al. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy[J]. J Viral Hepat, 2007, 14(1): 55-63.
[6] Testoni B, Ploss A. Cracking the host functional network involved in hepatitis B virus cccDNA biology[J]. Gut, 2023, 72(9): 1637-1639.
[7] Qi Z, Li G, Hu H, et al. Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice[J]. J Virol, 2014, 88(14): 8045-8056.
[8] 朱园飞, 李改云, 常豪, 等. 应用微环DNA技术体外诱导和制备重组的乙型肝炎病毒共价闭合环状DNA[J]. 微生物与感染, 2017, 12(04): 229-234.
[9] Li F, Cheng L, Murphy CM, et al. Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs[J]. Sci Rep, 2016, 6: 36483.
[10] YAN Z, ZENG J, YU Y, et al. HBVcircle: A novel tool to investigate hepatitis B virus covalently closed circular DNA[J]. J Hepatol, 2017, 66(6): 1149-1157.
[11] Wei L, Ploss A. Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation[J]. Nat Microbiol, 2020, 5(5): 715-726.
[12] Wei L, Ploss A. Hepatitis B virus cccDNA is formed through distinct repair processes of each strand[J]. Nat Commun, 2021, 12(1): 1591.
[13] Marchetti AL, Zhang H, Kim ES, et al. Proteomic Analysis of Nuclear Hepatitis B Virus Relaxed Circular DNA-Associated Proteins Identifies UV-Damaged DNA Binding Protein as a Host Factor Involved in Covalently Closed Circular DNA Formation[J]. J Virol, 2022, 96(2): e0136021.
[14] Kinoshita W, Ogura N, Watashi K, et al. Host factor PRPF31 is involved in cccDNA production in HBV-replicating cells[J]. Biochem Biophys Res Commun, 2017, 482(4): 638-644.
[15] Wang Y X, Niklasch M, Liu T, et al. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication[J]. J Hepatol, 2020, 72(5): 865-876.
[16] Verrier ER, Ligat G, Heydmann L, et al. Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target[J]. Gut, 2022, 72(9): 1745-1757.
[17] Zoulim F, Testoni B. Eliminating cccDNA to cure hepatitis B virus infection[J]. J Hepatol, 2023, 78(4): 677-680.
[18] Cai D, Mills C, Yu W, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation[J]. Antimicrob Agents Chemother, 2012, 56(8): 4277-4288.
[19] Liu C, Cai D, Zhang L, et al. Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA[J]. Antiviral Res, 2016, 134: 97-107.
[20] Chen D, Tan X, Chen W, et al. Discovery of Novel cccDNA Reducers toward the Cure of Hepatitis B Virus Infection[J]. J Med Chem, 2022, 65(16): 10938-10955.
[21] Wang L, Zhu Q, Zhang JD, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor[J]. J Hepatol, 2023, 78(4): 742-753. |
